PHILIP J. BARTER, M.D.; WILLIAM E. CONNOR, M.D., F.A.C.P.; ARTHUR A. SPECTOR, M.D.; MARK ARMSTRONG, M.D., F.A.C.P.; SONJA L. CONNOR, B.S.; MARY ANN NEWMAN, B.S.
Para-aminosalicylic acid (PAS-C®) was assessed as a hypolipidemic agent in 29 outpatients in 3 different studies. All patients had type II-a or II-b hyperlipoproteinemia. Six to eight grams of PAS-C® per day were given in four divided doses. Blood samples were collected at 2-week intervals during active and placebo periods. The first study involved 14 patients in a 12-week, double-blind crossover study. The mean serum cholesterol concentration was significantly lower with PAS-C® (310 ± 90 mg/100 ml) than with the placebo (367 ± 109 mg/100 ml) (P < 0.001). The mean serum triglyceride level likewise decreased, from 153 to 122 mg/100 ml (P < 0.01). Another 15 patients, studied in a 12-week, single-blind crossover study, had a similar lower serum cholesterol level with PAS-C® (296 ± 91 mg/100 ml with PAS-C® versus 365 ± 126 mg/100 ml with placebo, P < 0.001). Triglyceride levels also were reduced (139 to 108 mg/100 ml, P < 0.005). In the third study patients were given PAS-C® for 6 to 12 months, and similar results were noted. There were no decreases in effectiveness with time. This drug was effective and well tolerated.
BARTER PJ, CONNOR WE, SPECTOR AA, et al. Lowering of Serum Cholesterol and Triglyceride by Para-Aminosalicylic Acid in Hyperlipoproteinemia: Studies in Patients with Types II-A and II-B. Ann Intern Med. 1974;81:619–624. doi: 10.7326/0003-4819-81-5-619
Download citation file:
Published: Ann Intern Med. 1974;81(5):619-624.
Cardiology, Coronary Risk Factors, Dyslipidemia.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use